Dose-escalated radiotherapy plus long-term androgen deprivation therapy is safe and effective for patients with high-risk prostate cancer

Categories: Spring 2024

A study, recently presented at the American Society of Clinical Oncology Genitourinary

children and swing page 5 1
© Wade Douglas Carden, MD

Cancers Symposium in San Francisco found that high-risk prostate cancer patients benefit from dose-escalation radiotherapy in combination with long-term androgen deprivation therapy (ADT) with no increase in long-term toxicity.

The phase-3 trial of patients with high-risk prostate cancer and negative lymph node status was randomly assigned to receive either dose-escalated or conventional dose radiotherapy with ADT given to both groups.

The researchers found significantly improved biochemical or clinical progression-free survival in the dose- escalated group versus the conventional-dose group. Also, theresearchers found significant differences in prostate cancer-specific survival and overall survival. Late toxicities did not significantly differ between dose-escalated and conventional radiotherapy groups.

Oncology. February 4, 2024

Subscribe to Quest

"*" indicates required fields


This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*